An unforeseen marriage: Diabetes drug and chemoradiation effectively treat NSCLC

| | Health Imaging | Oncology Imaging

Pairing the diabetes drug, metformin, with chemoradiation therapy treatment for aggressive lung cancer may slow tumor growth and recurrence, according to researchers at the Perelman School of Medicine at the University of Pennsylvania. The researchers presented their preliminary findings during an oral abstract session on Oct. 28 at the 15th World Conference on Lung Cancer, according to a Penn Medicine news brief.

Preclinical and clinical results indicate that metformin is an effective radiosensitizer, making tumor cells more sensitive to radiation therapy, in treatment of stage III non-small cell lung cancer (NSCLC). Metformin is commonly used for type-2 diabetes and has past illustrated anti-cancer effects on numerous cancers, including prostate and colon.

Clinical evidence from 16 diabetic patients treated at the Hospital of the University of Pennsylvania between June 2008 and June 2013 with stage III A and B NSCLC and diabetes revealed that chemoradiation therapy, in combination with metformin, markedly improved local recurrence. After a median follow-up time of 10.4 months, only two local recurrences have occurred.

Learn more about the researchers’ findings here.

Penn Study: Diabetes Drug Metformin with Chemo and Radiation May Improve Outcom…

Related Content

High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer

Around the web

Radiology Business
Medical imaging trends to watch in 2025

The healthcare market analysis firm Signify Research released a list of predictions in radiology its analysts expect to see in 2025. 

Radiology Business
Ultrasound-first strategy for noncalcified lesions in DBT proves cost-effective

Jessica Porembka, MD, of the breast imaging division at University of Texas Southwestern Medical Center, said an ultrasound-first strategy for these lesions in DBT is cost-effective and improves efficiency. 

Radiology Business
Concerns about private equity's growing influence in radiology

Melissa Davis, MD, vice chair of medical informatics and associate professor at Yale University’s Department of Radiology and Biomedical Imaging, shares her findings from research on private equity market penetration.